Hoth Therapeutics Inc (NASDAQ:HOTH) Short Interest Down 71.3% in July

Hoth Therapeutics Inc (NASDAQ:HOTH) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 76,000 shares, a drop of 71.3% from the June 30th total of 265,200 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average trading volume of 690,100 shares, the short-interest ratio is presently 0.1 days.

Separately, Zacks Investment Research lowered Hoth Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday.

In other Hoth Therapeutics news, major shareholder Anthony Hayes sold 400,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $1.25, for a total value of $500,000.00. Following the sale, the insider now owns 1,130,674 shares of the company’s stock, valued at approximately $1,413,342.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 17.27% of the stock is currently owned by company insiders.

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Wedbush Securities Inc. acquired a new position in shares of Hoth Therapeutics Inc (NASDAQ:HOTH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 22,856 shares of the company’s stock, valued at approximately $59,000. Wedbush Securities Inc. owned approximately 0.17% of Hoth Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 0.24% of the company’s stock.

HOTH opened at $2.73 on Friday. The stock’s 50 day moving average price is $2.69 and its two-hundred day moving average price is $3.52. Hoth Therapeutics has a 12-month low of $2.31 and a 12-month high of $7.25.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01). Research analysts expect that Hoth Therapeutics will post -0.6 EPS for the current fiscal year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.

Featured Story: Determine Your Level of Risk Tolerance

Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with's FREE daily email newsletter.